• DNDi logo
  • COVID-19
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Hepatitis C
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Global Headquarters
      • DNDi DRC
      • DNDi East Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
DNDi logo
  • DNDi logo
  • COVID-19
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Hepatitis C
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Global Headquarters
      • DNDi DRC
      • DNDi East Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > Viewpoints

It takes more than good science to defeat a disease. Just look at the Nobel Prize.

Home > Viewpoints

It takes more than good science to defeat a disease. Just look at the Nobel Prize.

Protesters call for affordable access to hepatitis C medicines outside of international congress
12 Oct 2020
Share on twitter
Share on facebook
Share on linkedin
Share on email
Share on print

Viewpoint by

Dr Graciela Diap, HCV Access Project Leader, DNDi

As the world continues to reel from COVID-19, the Nobel Assembly is reminding us of an unpleasant truth about infectious diseases: While science and medical innovation are absolutely fundamental, winning the battle against deadly diseases requires political will.

The Nobel Prize in Medicine was awarded last week to scientists Harvey J. Alter, Michael Houghton, and Charles M. Rice for their discovery of the hepatitis C virus.

Thanks to their work, we now have the breakthrough medicines needed to cure the 71 million affected people worldwide.

The World Health Organization’s goal is to eliminate the disease by 2030. Very few countries are on track to meet that objective. Around 400,000 hepatitis C patients die every year – more than malaria.

In Latin America, where I come from, out of the 4 million people living with hepatitis C, only 1% receive treatment. The cure is effectively being rationed.

Patients are told all too often they are not sick enough to receive drugs. Come back when you are sicker, or in need of a liver transplant, they are told.

How can we explain this spectacular failure?

Hepatitis C is a blood-borne disease. It is known as the ‘silent epidemic’, as 80% of patients stay asymptomatic for years before developing cirrhosis, liver cancer, or a host of other health problems.

The disease baffled scientists for decades. Hepatitis A and B had been identified, but patients were developing another type of chronic hepatitis after receiving blood transfusions. A series of discoveries by this year’s Nobel laureates led to the discovery of this mystery illness in 1989.

Their scientific breakthrough opened up a new era of innovation for hepatitis C, allowing for the development of rapid diagnostic tests and eventually a generation of powerful drugs known as direct-acting antivirals. These revolutionary new oral treatments are safe and easy to use. They cure more than 90% of the patients who take them.

The old treatments involved months of injections with excruciating side effects. Direct-acting antivirals can cure the disease in as little as eight weeks. And unlike other infectious diseases such as AIDS, patients who complete treatment are then free of the virus, and will not pass the disease on to others.

These wonder cures make hepatitis C unique among infectious diseases. Treating everyone infected would halt transmission, even without a vaccine. We can realistically eliminate the disease.

Instead, we are treading water.

Every year, the number of new infections – 1.75 million – is practically the same as the total number of patients treated around the world.

What is going wrong?

The price of drugs, at first, was a substantial barrier. The first direct-acting antiviral to enter the market, sofosbuvir, came with an USD 84,000 price tag in the U.S. – a hefty 1,000 dollars for every single pill.

Under pressure from advocacy groups, governments have forcefully negotiated with companies. Experience shows that prices are low when governments fight for them to be low. Malaysia, for example had the courage to act, and issued a ‘government-use’ license to access generic sofosbuvir, enabling it offer free hepatitis C care in a number of public hospitals.

Generic competition is now possible in most countries. Prices have tumbled, with an internationally recognized treatment course of sofosbuvir and daclatasvir now under USD 80.

But many middle-income countries do not have access to these prices. Here, the onus is on the pharmaceutical companies to extend their price deals. My organization, the not-for-profit research and development organization Drugs for Neglected Diseases initiative (DNDi),  is in the final stages of developing an affordable direct-acting antiviral. We hope that this treatment can provide an accessible option for countries left behind.

In countries where treatment is affordable, governments need to step up. With aggressive screening campaigns and a simplified test and treat strategy, countries can find the ‘missing millions’ of silent patients, before they develop cirrhosis or cancer. And on a multilateral level, funding mechanisms are needed to facilitate drug procurement and to finance much-needed screening and treatment programmes.

The discovery of the hepatitis C virus by this year’s Nobel winners led to life-saving science and medical innovation. But this impressive scientific breakthrough has not yet led to an advance in public health.

We have all the health tools we need to bring an end to this silent epidemic. Yet we risk squandering an historic opportunity. What is lacking is political will, and global solidarity.

Published in Barron’s on 12 October 2020

Policy advocacy Hepatitis C

Read, watch, share

Viewpoints
18 Dec 2020

Gender and R&D: DNDi effectively mobilized

Doctor walking in front of the Hopital Saint Joseph
Press releases
24 Nov 2020

Largest clinical trial in Africa to treat COVID-19 cases before they become severe is launched in 13 countries

Dr Bernard Pécoul
Press releases
12 Nov 2020

Thailand’s Prince Mahidol Award honours Dr Bernard Pécoul, Founder of DNDi, for his service to public health

Healthcare worker with a patient in hospital setting
News
10 Nov 2020

Siriraj Institute of Clinical Research and DNDi to collaborate on initiatives to address the gaps in R&D and access to medicines

Healthcare worker in mask looks after Chagas patient
Press releases
13 Oct 2020

COVID-19: first set of specific healthcare recommendations issued for people living with Chagas disease

Healthcare worker with a patient in a hospital setting
Press releases
1 Oct 2020

DNDi welcomes GHIT Fund support for Phase I trial of novel treatment for cutaneous leishmaniasis

Young boy with healthcare worker at hospital setting
Press releases
29 Sep 2020

DRC: The Ministry of Health and DNDi launch a project designed to facilitate access to new treatments against sleeping sickness

Researchers in operation of the cell-based screening platform in the biosafety level-2(BSL-2) laboratory
Press releases
28 Sep 2020

Fundación MEDINA, DNDi, and Institut Pasteur Korea announce new funding from “la Caixa” Health Research for research partnership to discover new natural products against leishmaniasis and Chagas disease

VIEW ALL

Help neglected patients

To date, we have delivered eight new treatments, saving millions of lives.

We’re halfway to our goal of delivering 16-18 treatments by 2023. You can help us get there. 

GIVE NOW
DNDi logo
Facebook-f Twitter Instagram Linkedin-in Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License   
We use cookies to track our audience and improve our content. By continuing to browse our website, you are agreeing to our use of cookies.CLOSECOOKIE POLICY